Veterinary Medicines

Milbeguard Duo 16 mg / 40 mg film-coated tablets for cats

Authorised
  • Milbemycin oxime
  • Praziquantel
Download as PDF

Product identification

Medicine name:
Milbeguard Duo 16 mg / 40 mg film-coated tablets for cats
Milbeguard Duo 16 mg/40 mg filmomhulde tabletten voor katten
Active substance:
  • Milbemycin oxime
  • Praziquantel
Target species:
  • Cat
Route of administration:
  • Oral use

Product details

Active substance and strength:
  • Milbemycin oxime
    16.00
    milligram(s)
    /
    1.00
    Tablet
  • Praziquantel
    40.00
    milligram(s)
    /
    1.00
    Tablet
Pharmaceutical form:
  • Film-coated tablet
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QP54AB51
Legal status of supply:
  • Veterinary medicinal product not subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Netherlands
Package description:
  • Polyamide-Aluminium-Polyvinyl chloride / aluminium heat sealed blisters: Cardboard box with 50 blisters of 2 tablets (100 tablets).
  • Polyamide-Aluminium-Polyvinyl chloride / aluminium heat sealed blisters: Cardboard box with 24 blisters of 2 tablets (48 tablets).
  • Polyamide-Aluminium-Polyvinyl chloride / aluminium heat sealed blisters: Cardboard box with 12 blisters of 2 tablets (24 tablets).
  • Polyamide-Aluminium-Polyvinyl chloride / aluminium heat sealed blisters: Cardboard box with 5 blisters of 2 tablets (10 tablets).
  • Polyamide-Aluminium-Polyvinyl chloride / aluminium heat sealed blisters: Cardboard box with 2 blisters of 2 tablets (4 tablets).
  • Polyamide-Aluminium-Polyvinyl chloride / aluminium heat sealed blisters: Cardboard box with 1 blister of 2 tablets (2 tablets).

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Generic application (Article 18 of Regulation (EU) 2019/6)
Marketing authorisation holder:
  • Ceva Sante Animale
Marketing authorisation date:
Manufacturing sites for batch release:
  • Ceva Sante Animale
Responsible authority:
  • Medicines Evaluation Board
Authorisation number:
  • REG NL 130230
Date of authorisation status change:
Reference member state:
  • Ireland
Procedure number:
  • IE/V/0780/005
Concerned member states:
  • Austria
  • Belgium
  • Bulgaria
  • Croatia
  • Cyprus
  • Czechia
  • Denmark
  • Estonia
  • Finland
  • France
  • Germany
  • Greece
  • Hungary
  • Italy
  • Latvia
  • Lithuania
  • Luxembourg
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Romania
  • Slovakia
  • Slovenia
  • Spain
  • Sweden
  • United Kingdom (Northern Ireland)
Generic of:

Documents

Combined File of all Documents

This document does not exist in this language (English). You can find it in another language below.
Dutch (PDF)
Published on: 6/02/2024
Download

Summary of Product Characteristics

English (PDF)
Published on: 3/05/2024
Download